Connect Biopharma Holdings Limited

NASDAQ:CNTB

Biotechnology

Healthcare
$0.80 -4.09%

-$0.09 today

Market cap
$50.52M
Beta
-0.21
P/E (TTM)
-4.0
EPS (TTM)
-$0.50
52W Low $0.91High $3.82

Volume 2.50M

Average 0.30M

CNTB EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Connect Biopharma Holdings LimitedNASDAQ: CNTB

EBITDA · Q4 FY2025 · quarter ended Dec 2025

EBITDA remains negative

Q4 FY2025 EBITDA was -$14.9M, compared with -$8.64M a year earlier.

Context

  • EBITDA amounted to 85279.7% of revenue in FY2025, up 85223.0 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$54.42M (+0.3%) for the fiscal year ending Dec 2026, a step up from the -270.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$14.9M— QoQ
Last fiscal yearDec 2025
-$54.58M-270.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-72.4%——
1 year-270.2%+0.3%+270.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(54.58M) USD
Year-over-year change
-270.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CNTB compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -270.2% is the lowest of 9, against a peer median of +4.7%.
  • EBITDA amounts to 85279.7% of revenue for CNTB, versus a peer median of 2480.0%.
CNTB Competitors
EBITDA for CNTB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026-$24M USD+7.8%—337.0%
CNTXContext Therapeutics Inc.LTM Mar 2026-$40.18M USD-45.5%——
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.08M USD+36.5%——
STTKShattuck Labs, Inc.LTM Mar 2026-$46.23M USD+30.8%—4623.1%
IMAImageneBio IncLTM Mar 2026-$51.64M USD-7.8%——
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M USD-270.2%—85279.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$84.44M USD-35.4%——
STROSutro Biopharma, Inc.LTM Mar 2026-$106.12M USD+42.0%—106.5%
Peer median (excluding CNTB) —+4.7%—2480.0%

Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00026.03M64K
Cost of Revenue00000
Gross Profit00026.03M64K
Gross Margin———100.0%100.0%
Research & Development80.5M96.63M53M29.26M37.8M
Selling, General & Admin19.01M20.81M16.05M19.23M20.34M
Operating Expenses98.11M119.32M69.06M48.49M58.14M
Depreciation & Amortization634K1.03M720K660K704K
EBITDA(201.36M)(116.74M)(61.27M)(14.75M)(54.58M)
EBITDA Margin———-56.6%-85279.7%
Operating Income(98.11M)(119.32M)(69.06M)(22.45M)(58.07M)
Operating Margin———-86.2%-90740.6%
Interest Income97.67K1.56M5.2K4.45M2.27M
Interest Expense6.91K21.03K000
Other Income / Expenses(103.89M)1.52M7.07M7.05M2.79M
Income Before Tax(202M)(117.79M)(61.99M)(15.41M)(55.28M)
Pre-Tax Margin———-59.2%-86379.7%
Income Tax Expense266K298K120K223K197K
Net Income(202.27M)(118.09M)(62.11M)(15.63M)(55.48M)
Net Margin———-60.0%-86687.5%
EPS (Basic)(25.00)(14.50)(1.08)(0.28)(1.00)
EPS (Diluted)(25.00)(14.50)(1.08)(0.28)(1.00)
Weighted Avg Shares52.27M55.04M55.07M55.21M55.66M
Weighted Avg Shares (Diluted)52.27M55.04M55.07M55.21M55.66M

Connect Biopharma Holdings Limited

NASDAQ:CNTB

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.